Sanders, Cummings Announce Congressional Investigation into Marathon’s Recently Approved Emflaza® (deflazacort)
On February 9, FDA announced approval of a new drug to treat Duchenne muscular dystrophy. In fact, NDAs 208684 and 20685 (oral tablets 6, 18, 30, and 36 mg and oral suspension 22.75 mg/mL), both orphan drugs, were approved that day. However, by February 13, Reuters reported that “Marathon pauses Duchenne drug launch amid price outcry”.…